These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 27275946)

  • 1. Discovery of the Potent and Selective M1 PAM-Agonist N-[(3R,4S)-3-Hydroxytetrahydro-2H-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4-yl)benzyl]pyridine-2-carboxamide (PF-06767832): Evaluation of Efficacy and Cholinergic Side Effects.
    Davoren JE; Lee CW; Garnsey M; Brodney MA; Cordes J; Dlugolenski K; Edgerton JR; Harris AR; Helal CJ; Jenkinson S; Kauffman GW; Kenakin TP; Lazzaro JT; Lotarski SM; Mao Y; Nason DM; Northcott C; Nottebaum L; O'Neil SV; Pettersen B; Popiolek M; Reinhart V; Salomon-Ferrer R; Steyn SJ; Webb D; Zhang L; Grimwood S
    J Med Chem; 2016 Jul; 59(13):6313-28. PubMed ID: 27275946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probing the binding site of novel selective positive allosteric modulators at the M
    Khajehali E; Valant C; Jörg M; Tobin AB; Conn PJ; Lindsley CW; Sexton PM; Scammells PJ; Christopoulos A
    Biochem Pharmacol; 2018 Aug; 154():243-254. PubMed ID: 29777683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for Classical Cholinergic Toxicity Associated with Selective Activation of M1 Muscarinic Receptors.
    Alt A; Pendri A; Bertekap RL; Li G; Benitex Y; Nophsker M; Rockwell KL; Burford NT; Sum CS; Chen J; Herbst JJ; Ferrante M; Hendricson A; Cvijic ME; Westphal RS; O'Connell J; Banks M; Zhang L; Gentles RG; Jenkins S; Loy J; Macor JE
    J Pharmacol Exp Ther; 2016 Feb; 356(2):293-304. PubMed ID: 26582730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and Synthesis of γ- and δ-Lactam M
    Davoren JE; Garnsey M; Pettersen B; Brodney MA; Edgerton JR; Fortin JP; Grimwood S; Harris AR; Jenkinson S; Kenakin T; Lazzaro JT; Lee CW; Lotarski SM; Nottebaum L; O'Neil SV; Popiolek M; Ramsey S; Steyn SJ; Thorn CA; Zhang L; Webb D
    J Med Chem; 2017 Aug; 60(15):6649-6663. PubMed ID: 28598634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diverse Effects on M
    Rook JM; Abe M; Cho HP; Nance KD; Luscombe VB; Adams JJ; Dickerson JW; Remke DH; Garcia-Barrantes PM; Engers DW; Engers JL; Chang S; Foster JJ; Blobaum AL; Niswender CM; Jones CK; Conn PJ; Lindsley CW
    ACS Chem Neurosci; 2017 Apr; 8(4):866-883. PubMed ID: 28001356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. M
    Walker LC; Campbell EJ; Huckstep KL; Chen NA; Langmead CJ; Lawrence AJ
    Pharmacol Res Perspect; 2022 Feb; 10(1):e00907. PubMed ID: 34962108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological characterization of LY593093, an M1 muscarinic acetylcholine receptor-selective partial orthosteric agonist.
    Watt ML; Schober DA; Hitchcock S; Liu B; Chesterfield AK; McKinzie D; Felder CC
    J Pharmacol Exp Ther; 2011 Aug; 338(2):622-32. PubMed ID: 21558436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and optimization of selective azaindole amide M1 positive allosteric modulators.
    Davoren JE; O'Neil SV; Anderson DP; Brodney MA; Chenard L; Dlugolenski K; Edgerton JR; Green M; Garnsey M; Grimwood S; Harris AR; Kauffman GW; LaChapelle E; Lazzaro JT; Lee CW; Lotarski SM; Nason DM; Obach RS; Reinhart V; Salomon-Ferrer R; Steyn SJ; Webb D; Yan J; Zhang L
    Bioorg Med Chem Lett; 2016 Jan; 26(2):650-655. PubMed ID: 26631313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Approach to Discovering Novel Muscarinic M
    Kurimoto E; Matsuda S; Shimizu Y; Sako Y; Mandai T; Sugimoto T; Sakamoto H; Kimura H
    J Pharmacol Exp Ther; 2018 Jan; 364(1):28-37. PubMed ID: 29025977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. M1 muscarinic acetylcholine receptors: A therapeutic strategy for symptomatic and disease-modifying effects in Alzheimer's disease?
    Scarpa M; Hesse S; Bradley SJ
    Adv Pharmacol; 2020; 88():277-310. PubMed ID: 32416870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of N-[6-(Substituted Aminoethylideneamino)-2-Hydroxyindan-1-yl]arylamides as selective and potent muscarinic M₁ agonists.
    Liu B; Croy CH; Hitchcock SA; Allen JR; Rao Z; Evans D; Bures MG; McKinzie DL; Watt ML; Stuart Gregory G; Hansen MM; Hoogestraat PJ; Jamison JA; Okha-Mokube FM; Stratford RE; Turner W; Bymaster F; Felder CC
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4158-63. PubMed ID: 26299349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. M
    Moran SP; Dickerson JW; Cho HP; Xiang Z; Maksymetz J; Remke DH; Lv X; Doyle CA; Rajan DH; Niswender CM; Engers DW; Lindsley CW; Rook JM; Conn PJ
    Neuropsychopharmacology; 2018 Jul; 43(8):1763-1771. PubMed ID: 29581537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dronedarone Modulates M1 and M3 Muscarinic Receptors with Subtype Selectivity, Functional Selectivity, and Probe Dependence.
    Jayasuriya GM; Elmslie G; Burstein ES; Ellis J
    Pharmacology; 2017; 99(3-4):128-138. PubMed ID: 27992867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel M
    Rook JM; Bertron JL; Cho HP; Garcia-Barrantes PM; Moran SP; Maksymetz JT; Nance KD; Dickerson JW; Remke DH; Chang S; Harp JM; Blobaum AL; Niswender CM; Jones CK; Stauffer SR; Conn PJ; Lindsley CW
    ACS Chem Neurosci; 2018 Sep; 9(9):2274-2285. PubMed ID: 29701957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SAR studies on carboxylic acid series M(1) selective positive allosteric modulators (PAMs).
    Kuduk SD; Beshore DC
    Curr Top Med Chem; 2014; 14(15):1738-54. PubMed ID: 25176125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AF710B, a Novel M1/σ1 Agonist with Therapeutic Efficacy in Animal Models of Alzheimer’s Disease.
    Fisher A; Bezprozvanny I; Wu L; Ryskamp DA; Bar-Ner N; Natan N; Brandeis R; Elkon H; Nahum V; Gershonov E; LaFerla FM; Medeiros R
    Neurodegener Dis; 2016; 16(1-2):95-110. PubMed ID: 26606130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of N-substituted 7-azaindoline derivatives as potent, orally available M1 and M4 muscarinic acetylcholine receptors selective agonists.
    Takai K; Inoue Y; Konishi Y; Suwa A; Uruno Y; Matsuda H; Nakako T; Sakai M; Nishikawa H; Hashimoto G; Enomoto T; Kitamura A; Uematsu Y; Kiyoshi A; Sumiyoshi T
    Bioorg Med Chem Lett; 2014 Jul; 24(14):3189-93. PubMed ID: 24856064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PF-06827443 Displays Robust Allosteric Agonist and Positive Allosteric Modulator Activity in High Receptor Reserve and Native Systems.
    Moran SP; Cho HP; Maksymetz J; Remke DH; Hanson RM; Niswender CM; Lindsley CW; Rook JM; Conn PJ
    ACS Chem Neurosci; 2018 Sep; 9(9):2218-2224. PubMed ID: 29683646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The M1 muscarinic receptor allosteric agonists AC-42 and 1-[1'-(2-methylbenzyl)-1,4'-bipiperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one bind to a unique site distinct from the acetylcholine orthosteric site.
    Jacobson MA; Kreatsoulas C; Pascarella DM; O'Brien JA; Sur C
    Mol Pharmacol; 2010 Oct; 78(4):648-57. PubMed ID: 20660086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 6-Phenylpyrimidin-4-ones as Positive Allosteric Modulators at the M
    Jörg M; van der Westhuizen ET; Khajehali E; Burger WAC; White JM; Choy KHC; Tobin AB; Sexton PM; Valant C; Capuano B; Christopoulos A; Scammells PJ
    ACS Chem Neurosci; 2019 Mar; 10(3):1099-1114. PubMed ID: 30547573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.